AMD

Gene therapy in AMD: Promises and challenges

Gene therapy could offer long-term stable control and prevent non-compliance, but the long-term effectiveness remains to be seen.

Gene therapy and editing for the retina: A primer

A look at advances in gene replacement therapy, gene delivery and CRISPR technology.

Is drier better in neovascular AMD?

It may depend on the location of the fluid. A quick look at HARBOR post-hoc results.

Pipeline Report: Despite major approvals, the queue gets longer

Treatments for exudative disease were notable for four significant exits from our listing and seven new entries this year.

Pipeline Report: The path to GA treatment: What’s hot, what’s not

A review of past trials that disappointed and current trials that are showing promise as potential treatments.

First results of gene and cell therapies for nAMD, RP, plus ...

Findings on predictors of endophthalmitis, widefield OCT-A vs. FA and microsecond pulsing laser make five worthy takeaways.

Downside of finger flicks, upside of abicipar changes

These findings and three other presentations on SRF/IRF, stable CST and oral therapy give new insights into nAMD.

20 milestones ahead in AMD, DME meds

A look at chemical and biologic agents queued this year or next for key steps toward commercialization.

Targeting Unmet Needs in nAMD Treatment

A look at longer-acting anti-VEGF agents, sustained-release delivery, gene therapy and novel molecules in development.

Video Vault

Minimally invasive management of lenticular deposits

Akshay Thomas, MD, MS, of Tennessee Retina demonstrates his surgical technique for removing posterior intraocular lens deposits.